Written By: David Statman
Mesothelioma clinical trials give patients access to innovative therapies and new approaches not yet approved by the U.S. Food and Drug Administration (FDA). For example, some studies test combination strategies pairing surgery with other mesothelioma treatment options — options that are not currently FDA-approved but may improve outcomes.
Medically reviewed for accuracy by
Dr. Stephen Williams
Precision Oncology Scientist
JUMP TO A TOPIC
A clinical trial is a carefully designed study to test a new therapy or treatment approach for diseases such as cancer. Trials are the foundation of medical advancements, serving as the testing ground for different therapies that eventually could become the standard of care for patients.
Clinical trials are typically offered through leading cancer centers and top hospitals. When a patient is diagnosed, their doctor may discuss enrolling in a clinical trial, either at their hospital or another specialized center, as one of the available options for treatment.
One of the most important aspects of clinical trials is accessibility and affordability. In many cases, patients do not have to pay for the experimental treatment being tested. This not only opens the door to potentially lifesaving care but can also save patients and their families tens of thousands of dollars in medical costs.
Clinical trials for mesothelioma focus on:
Clinical trials can benefit patients at different stages of cancer, though they are often most valuable for those with advanced disease. Patients with stage 3 or stage 4 cancer are frequently offered a spot in a clinical trial, especially when surgery is no longer an option and standard FDA-approved therapies provide only limited survival benefits.
However, clinical trials are not just for late-stage patients. Many phase 1 and phase 2 studies specifically enroll patients with early-stage cancers (stages 1 and 2). Researchers often seek patients with better overall health and stronger survival chances to evaluate how new therapies perform under optimal conditions and help the therapy perform well to progress it to larger studies.
Mesothelioma clinical trials are medical studies used to test new treatment approaches for this disease. Clinical trials give hope, especially to people diagnosed with mesothelioma. Doctors and researchers use mesothelioma clinical trials to investigate, and hopefully prove, the effectiveness and safety of new advanced treatment methods.
One of the benefits of mesothelioma specialists and cancer centers is their ability to connect patients with clinical trials. Mesothelioma treatments and diagnostic procedures in use today have gone through clinical testing to ensure quality and safety.
The testing process, from concept to FDA approval, is lengthy. Medical breakthroughs for mesothelioma may exist, but they are not yet formally approved.
If you have been diagnosed with mesothelioma, enrolling in a clinical trial may provide you an opportunity to receive new treatments still being studied. Most participants of mesothelioma clinical trials have already been used to approve standard mesothelioma treatment options and are seeking additional therapeutic options. Strict regulations and procedures control these trials to ensure patient safety.
New treatments may come in the form of radiation, chemotherapy, immunotherapy, new drug combinations, virotherapy, or multimodal therapy that includes surgery. Clinical trials may someday help patients achieve long term remission and even cure mesothelioma.
You can learn more about clinical trials in our free Mesothelioma Guide.
Before a medication or treatment for mesothelioma can be approved by the FDA, it must go through a series of clinical trial phases to ensure it is both safe and effective. Most pass through at least three phases, with some continuing into a fourth phase for long-term monitoring.
Phase 1
Phase 1 clinical trials for mesothelioma test a new treatment in a small group of participants. The goals are to determine:
According to the FDA, phase 1 trials typically last several months and enroll fewer participants than later phases. This stage provides the foundation for developing future studies.
Phase 2
Phase 2 clinical trials for mesothelioma focus on the effectiveness of the treatment. Researchers focus on:
According to the FDA, phase 2 trials can take up to two years to complete.
Phase 3
Phase 3 clinical trials for mesothelioma are often the final step before FDA approval. In this phase, researchers compare the new treatment to current standard therapies, evaluating:
Participants are usually randomized into two groups: one receives the new therapy, and the other receives standard treatment (the control group). This allows researchers to directly compare outcomes. Phase 3 trials may take up to four years to complete.
Phase 4
Phase 4 clinical trials for mesothelioma are defined as post-approval studies, meaning the FDA has already approved the treatment for general patient use. These studies are designed to monitor the new treatment for long-term safety, effectiveness, and optimal use.
Researchers will evaluate how the treatment performs in larger, more diverse populations over time. There is no set timeline for completion of this phase, as ongoing observation is often required.
Participation in a clinical trial is voluntary and requires informed consent. Before enrollment, patients receive comprehensive information about the study’s purpose, procedures, risks, and potential benefits from their doctor. Those who agree to participate will sign a consent form. Patients may choose to leave the trial at any time if they no longer wish to continue.
Clinical trials have specific enrollment criteria. Patients must meet these criteria to participate and are individually evaluated using test-related specifications:
Age
Certain trials may test a treatment on a specific age group (example: 45-55). This disqualifies anyone older or younger than the specified age range.
Gender
Certain studies may only apply to women (example: dual treatments targeting ovarian cancer and peritoneal mesothelioma). Other trials may use male hormones that would exclude women.
Current health
The current or past health of a patient may determine whether certain trials accept them. Some trials will exclude patients with particular medical conditions or histories.
Mesothelioma type and/or stage
Certain trials focus on a specific mesothelioma type or stage (example: stage 2 pleural mesothelioma).
Past treatment
Some studies exclude patients — or look to enroll patients — who have already undergone a specific treatment (example: surgery, chemotherapy, or radiation). Studies may exclude patients who have already participated in a similar study (example: a previous immunotherapy study).
Candidacy for future surgery
Many studies may exclude or enroll patients based on whether they are candidates for surgery.
Patients are accepted or denied based on these qualifications. There are many ongoing clinical trials for mesothelioma. If a patient is rejected from one trial, they should still apply to others.
Some people hesitate to enroll in clinical trials due to use of control groups and placebo-controlled trials.
In placebo-controlled trials, half the participants receive the drug being tested, while the other half receive a “placebo.” The placebo is a pill that looks identical to the actual drug but doesn’t contain any medicine. Those who get the placebo are chosen randomly, making the study “randomized.” A “double-blind” trial means neither the doctors nor the participants know who got a placebo.
Understanding your options and how these studies help may alleviate concerns.
Placebos allow researchers to compare outcomes directly. This helps them quickly determine whether the experimental drug is truly effective. Without a placebo group, it would be difficult to measure if improvements are due to the drug itself or other factors.
Participants in placebo-controlled trials are closely monitored by top specialists. If a patient’s condition worsens, their doctor will intervene, discuss options, and ensure the patient’s well-being comes first. Patients always retain the right to leave a trial at any time.
Choosing to participate in a placebo-controlled trial is a personal decision. For many patients — especially those who have already tried standard therapies — clinical trials may represent the best opportunity to access new treatments and extend survival. Speaking with a patient advocate or mesothelioma specialist can help you weigh your options and find the trial that’s right for you.
Sources & Author
Mesothelioma clinical trials are research studies that explore new and potentially better ways to treat this challenging disease. These trials are essential for advancing medical knowledge and offer hope to patients by providing access to innovative therapies that are not yet approved by the U.S. Food and Drug Administration (FDA). Participation in a clinical trial may include trying new drugs, combination treatments, or novel surgical techniques. Often, these studies are conducted at leading cancer centers and top hospitals, where patient safety and care are prioritized. Many of these trials are offered at reduced cost or free, making them an accessible option for those seeking additional treatment choices beyond standard options.
Clinical trials are carefully designed to answer specific questions about the safety and effectiveness of new treatments. They usually proceed through several phases, beginning with small groups of patients to assess safety and dosage, then expanding to larger groups to examine how well the treatment works. Ultimately, successful trials can lead to new therapies being approved for general use, potentially improving outcomes for future patients. In addition to testing drugs, these studies may focus on early detection, accurate diagnosis, and improving patients' quality of life during treatment. They serve as a vital pathway for developing the next generation of mesothelioma treatments.
Enrolling in a clinical trial is a voluntary decision made by the patient after discussing the potential benefits and risks with their healthcare provider. Strict guidelines determine who is eligible to participate, and each individual is thoroughly evaluated to ensure they meet the specific criteria for a given study. Patients can choose to leave a trial at any time if they wish, and their health and safety are always a priority. These trials frequently include sophisticated research methods, such as placebo-controlled and double-blind studies, which help ensure the reliability of results. Such methods allow scientists to compare new treatments against existing ones or simple placebos, providing clearer evidence of effectiveness and safety.
For many patients with advanced mesothelioma, clinical trials offer the best chance to access cutting-edge therapies that may extend survival or improve quality of life. Past participants have often found great benefit, and their stories provide inspiration and hope to others facing this diagnosis. If you are considering joining a clinical trial, consulting with your healthcare team or a mesothelioma specialist can help you understand your options. While participation involves careful consideration, it is a meaningful way to contribute to advances in mesothelioma care and may introduce you to new treatment pathways that could benefit your health and future well-being.
